Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Klimek, Ewa ^a   Skalska, Anna ^a   Kwaśny Krochin, Beata ^a   Surdacki, Andrzej ^a   Sulicka, Joanna ^a   Korkosz, Mariusz ^a   Fedak, Danuta ^a   Kierzkowska, Izabella ^a   Wizner, Barbara ^a   Grodzicki, Tomasz K ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPROTEGERIN; PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; N,N-DIMETHYLARGININE; SERUM AMYLOID P;

ADULT; ARTICLE; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; JOINT; MALE; RHEUMATOID ARTHRITIS; ANALOGS AND DERIVATIVES; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; ARGININE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; E-SELECTIN; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RISK FACTORS; SERUM AMYLOID P-COMPONENT; VASCULAR CELL ADHESION MOLECULE-1; VON WILLEBRAND FACTOR;

EID: 84901022887     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/681635     Document Type: Article

References (59)

1. Kremers H. M., Crowson C. S., Therneau T. M., Roger V. L., Gabriel S. E., High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis and Rheumatism 2008 58 8 2268 2274 2-s2.0-49449098214 10.1002/art.23650
2. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Martin J., Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Seminars in Arthritis and Rheumatism 2005 35 1 8 17 2-s2.0-23444439778 10.1016/j.semarthrit. 2005.03.004
3. del Rincón I. D., Williams K., Stern M. P., Freeman G. L., Escalante A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis and Rheumatology 2001 44 12 2737 2745 10.1002/1529-0131(200112)44:12<2737:: AID-ART460>3.0.CO;2-#
4. Gonzalez A., Maradit Kremers H., Crowson C. S., Ballman K. V., Roger V. L., Jacobsen S. J., O'Fallon W. M., Gabriel S. E., Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Annals of the Rheumatic Diseases 2008 67 1 64 69 2-s2.0-37749039808 10.1136/ard.2006.059980
5. Surdacki A., Martens-Lobenhoffer J., Wloch A., Marewicz E., Rakowski T., Wieczorek-Surdacka E., Dubiel J. S., Pryjma J., Bode-Böger S. M., Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis and Rheumatism 2007 56 3 809 819 2-s2.0-33947151033 10.1002/art.22424
6. Foster W., Lip G. Y. H., Raza K., Carruthers D., Blann A. D., An observational study of endothelial function in early arthritis. European Journal of Clinical Investigation 2012 42 5 510 516 2-s2.0-84859698912 10.1111/j.1365-2362.2011.02607.x
7. Bergholm R., Leirisalo-Repo M., Vehkavaara S., Mäkimattila S., Taskinen M., Yki-Järvinen H., Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 10 1637 1641 2-s2.0-0036790545 10.1161/01.ATV. 0000033516.73864.4E
8. Södergren A., Karp K., Boman K., Eriksson C., Lundström E., Smedby T., Söderlund L., Rantapää-Dahlqvist S., Wållberg-Jonsson S., Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Research and Therapy 2010 12 article R158
9. González-Gay M. A., González-Juanatey C., Inflammation, endothelial function and atherosclerosis in rheumatoid arthritis. Arthritis Research and Therapy 2012 14 article 122
10. Rodríguez-Rodríguez L., González-Juanatey C., García-Bermúdez M., Vázquez-Rodríguez T. R., Miranda-Filloy J. A., Fernández-Gutiérrez B., Llorca J., Martin J., González-Gay M. A., CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Research and Therapy 2011 13 article R133 10.1186/ar3444
11. Sattar N., McCarey D. W., Capell H., McInnes I. B., Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003 108 24 2957 2963 2-s2.0-0346365086 10.1161/01.CIR.0000099844.31524.05
12. Del Rincón I., Williams K., Stern M. P., Freeman G. L., O'Leary D. H., Escalantel A., Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis and Rheumatism 2003 48 7 1833 1840 2-s2.0-0038005022 10.1002/art.11078
13. Hannawi S., Haluska B., Marwick T. H., Thomas R., Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Research and Therapy 2007 9 6, article R116 2-s2.0-36949008570 10.1186/ar2323
14. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A. Jr., Mitchell D. M., Neustadt D. H., Pinals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder G. G., The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988 31 3 315 324 2-s2.0-0023945481
15. Prevoo M. L. L., van 'T Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B. A., van Riel P. L. C. M., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 1995 38 1 44 48 2-s2.0-0028815803 10.1002/art.1780380107
16. Levey A. S., A simplified equation to predict GFR from serum creatinine. The American Journal of Kidney Diseases 2002 39 2, supplement S76 110 10.1053/ajkd.2002.30944
17. Tonstad S., Johnston J. A., Cardiovascular risks associated with smoking: a review for clinicians. European Journal of Cardiovascular Prevention and Rehabilitation 2006 13 4 507 514 2-s2.0-33746694242 10.1097/01.hjr.0000214609. 06738.62
18. Baka Z., Buzás E., Nagy G., Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Research and Therapy 2009 11 4 238 10.1186/ar2751 2-s2.0-73349089655
19. Choy E., Sattar N., Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Annals of the Rheumatic Diseases 2009 68 4 460 469 2-s2.0-64949111191 10.1136/ard.2008.101964
20. Myasoedova E., Crowson C. S., Kremers H. M., Roger V. L., Fitz-Gibbon P. D., Therneau T. M., Gabriel S. E., Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Annals of the Rheumatic Diseases 2011 70 3 482 487 2-s2.0-79951517914 10.1136/ard.2010.135871
21. Angelidis C., Deftereos S., Giannopoulos G., Anatoliotakis N., Bouras G., Hatzis G., Panagopoulou V., Pyrgakis V., Cleman M. W., Cystatin C: an emerging biomarker in cardiovascular disease. Current Topics in Medicinal Chemistry 2013 13 2 164 179 10.2174/1568026611313020006
22. Skalska A., Klimek E., Wizner B., Gowski J., Grodzicki T., Kidney function and thickness of carotid intima-media complex in patients with treated arterial hypertension. Blood Pressure 2007 16 6 367 374 2-s2.0-36849086111 10.1080/08037050701642675
23. Inoue K., Kodama T., Daida H., Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. International Journal of Vascular Medicine 2012 2012 6 657025 10.1155/2012/657025
24. Stpień E., Osteoprotegerin as a possible novel predictor of cardiovascular dysfunction. Kardiochirurgia i Torakochirurgia Polska 2012 9 1 82 85 2-s2.0-84860186055
25. Jenny N. S., Arnold A. M., Kuller L. H., Tracy R. P., Psaty B. M., Associations of pentraxin 3 with cardiovascular disease and all-cause death: the cardiovascular health study. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 4 594 599 2-s2.0-63449095760 10.1161/ATVBAHA.108.178947
26. Lieb W., Gona P., Larson M. G., Massaro J. M., Lipinska I., Keaney J. F., Rong J., Corey D., Hoffmann U., Fox C. S., Vasan R. S., Benjamin E. J., Odonnell C. J., Kathiresan S., Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 9 1849 1854 2-s2.0-77955983144 10.1161/ATVBAHA.109.199661
27. Mangan S. H., van Campenhout A., Rush C., Golledge J., Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor- associated with induction of angiopoietin-2. Cardiovascular Research 2007 76 3 494 505 2-s2.0-35548975135 10.1016/j.cardiores.2007.07.017
28. Gonzales-Gay M. A., Garcia-Unzueta M. T., de Matias J. M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., Martin J., Ilorca J., Influence of anti-TNF- infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2006 24 4 373 379 2-s2.0-33748519856
29. Dessein P. H., Joffe B. I., Singh S., Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Research and Therapy 2005 7 3 R634 R643 2-s2.0-28444457810
30. Bloom B. J., Miller L. C., Tucker L. B., Schaller J. G., Blier P. R., Soluble adhesion molecules in juvenile rheumatoid arthritis. Journal of Rheumatology 1999 26 9 2044 2048 2-s2.0-0033454107
31. Hürlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., Béchir M., Spieker L. E., Neidhart M., Michel B. A., Gay R. E., Lüscher T. F., Gay S., Ruschitzka F., Anti-tumor necrosis factor- treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002 106 17 2184 2187 2-s2.0-0037159293 10.1161/01.CIR.0000037521. 71373.44
32. Sandoo A., Kitas G. D., Carroll D., van Zanten J. J. V., The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Research and Therapy 2012 14 article R117
33. Danesh J., Wheeler J. G., Hirschfield G. M., Eda S., Eiriksdottir G., Rumley A., Lowe G. D. O., Pepys M. B., Gudnason V., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England Journal of Medicine 2004 350 14 1387 1397 2-s2.0-1842587885 10.1056/NEJMoa032804
34. Balanescu S., Calmac L., Constantinescu D., Marinescu M., Onut R., Dorobantu M., Systemic inflammation and early atheroma formation: are they related? Maedica 2010 5 292 301
35. Venugopal S. K., Devaraj S., Yuhanna I., Shaul P., Jialal I., Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002 106 12 1439 1441 2-s2.0-0037126012 10.1161/01.CIR.0000033116.22237.F9
36. Yoshizumi M., Perrella M. A., Burnett J. C. Jr., Lee M. E., Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circulation Research 1993 73 1 205 209 2-s2.0-0027233868
37. Hermann C., Assmus B., Urbich C., Zeiher A. M., Dimmeler S., Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 2 402 409 2-s2.0-0033964671
38. Ito A., Tsao P. S., Adimoolam S., Kimoto M., Ogawa T., Cooke J. P., Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999 99 24 3092 3095 2-s2.0-0033594888
39. Gonzalez-Juanatey C., Llorca J., Sanchez Andrade A., Garcia-Porrua C., Martin J., Gonzalez-Gay M. A., Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clinical and Experimental Rheumatology 2006 24 3 309 312 2-s2.0-33744792493
40. Brennan F. M., Jackson A., Chantry D., Maini R., Feldmann M., Inhibitory effect of TNF antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. The Lancet 1989 2 8657 244 247 2-s2.0-0024314554
41. Nishimoto N., Kishimoto T., Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology 2006 2 11 619 626 2-s2.0-33750474405 10.1038/ncprheum0338
42. Dessein P. H., Joffe B. I., Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clinical and Experimental Rheumatology 2006 24 2 161 167 2-s2.0-33744808528
43. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Piñeiro A., Garcia-Porrua C., Testa A., Llorca J., High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. Journal of Rheumatology 2005 32 7 1219 1223 2-s2.0-22244456685
44. Vaudo G., Marchesi S., Gerli R., Allegrucci R., Giordano A., Siepi D., Pirro M., Shoenfeld Y., Schillaci G., Mannarino E., Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Annals of the Rheumatic Diseases 2004 63 1 31 35 2-s2.0-9144252008 10.1136/ard.2003.007740
45. González-Gay M. A., González-Juanatey C., Miranda-Filloy J. A., García-Unzueta M. T., Llorca J., Lack of association between flow-mediated endothelium-dependent vasodilatation and biomarkers of endothelial dysfunction in patients with severe rheumatoid arthritis. Rheumatology International 2012 32 12 4071 4072 10.1007/s00296-011-2254-7
46. Kwaśny-Krochin B., Głuszko P., Undas A., Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation. Polskie Archiwum Medycyny Wewnȩtrznej 2012 122 270 276
47. Sandoo A., Dimitroulas T., Toms T. E., Hodson J., van Zanten J. J. V., Smith J. P., Kitas G. D., Clinical remission following treatment with tumor necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clinical Biochemistry 2012 45 16-17 1399 1403 10.1016/j.clinbiochem.2012.07.092
48. Surdacki A., Martens-Lobenhoffer J., Wloch A., Gluszko P., Rakowski T., Dubiel J. S., Bode-Böger S. M., Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism 2009 58 3 316 318 2-s2.0-59649112835 10.1016/j.metabol. 2008.10.002
49. Turiel M., Atzeni F., Tomasoni L., de Portu S., Delfino L., Bodini B. D., Longhi M., Sitia S., Bianchi M., Ferrario P., Doria A., de Gennaro Colonna V., Sarzi-Puttini P., Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology 2009 48 7 834 839 2-s2.0-67650096908 10.1093/rheumatology/kep082
50. Korkosz M., Sulicka J., Surdacki A., Dimethylated L-arginine analogues versus autoantibodies in early rheumatoid arthritis. Scandinavian Journal of Rheumatology 2012 41 1 82 83 2-s2.0-84856443264 10.3109/03009742.2011.630329
51. Sandoo A., Dimitroulas T., van Zanten J. J. V., Smith J. P., Metsios G. S., Nightingale P., Stavropoulos-Kalinoglou A., Kitas G. D., Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2012 30 388 396
52. Di Franco M., Spinelli F. R., Metere A., Gerardi M. C., Conti V., Boccalini F., Iannuccelli C., Ciciarello F., Agati L., Valesini G., Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators of Inflammation 2012 2012 7 347268 10.1155/2012/347268
53. Turiel M., Tomasoni L., Sitia S., Cicala S., Gianturco L., Ricci C., Atzeni F., de Gennaro Colonna V., Longhi M., Sarzi-Puttini P., Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovascular Therapeutics 2010 28 5 e53 e64 2-s2.0-77955267720 10.1111/j.1755-5922.2009.00119.x
54. Böger R. H., Sydow K., Borlak J., Thum T., Lenzen H., Schubert B., Tsikas D., Bode-Böger S. M., LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circulation Research 2000 87 2 99 105 2-s2.0-0034698038
55. Surdacki A., L-arginine analogs-inactive markers or active agents in atherogenesis? Cardiovascular and Hematological Agents in Medicinal Chemistry 2008 6 4 302 311 2-s2.0-54949108228 10.2174/187152508785909429
56. Marliss E. B., Chevalier S., Gougeon R., Morais J. A., Lamarche M., Adegoke O. A. J., Wu G., Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006 49 2 351 359 2-s2.0-31844456075 10.1007/s00125-005-0066-6
57. Dimitroulas T., Sandoo A., van Zanten J. J. V., Smith J. P., Hodson J., Metsios G. S., Stavropoulos-Kalinoglou A., Kitas G. D., Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. Scandinavian Journal of Rheumatology 2013 42 3 176 181 10.3109/03009742.2012.747627
58. Surdacki A., Kruszelnicka O., Rakowski T., Jaźwińska-Kozuba A., Dubiel J. S., Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study. Cardiovascular Diabetology 2013 12 article 64
59. Genre F., López-Mejías R., Miranda-Filloy J. A., Carnero-López B., Gómez-Acebo I., Blanco R., Ochoa R., Rueda J., González-Juanatey C., Llorca J., González-Gay M. A., Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- antagonist therapy. Clinical and Experimental Rheumatology 2013 31 5 749 755